Antibiotic resistance is one of the most pressing—and quietly advancing—challenges facing modern medicine. Among the most dangerous bacterial pathogens driving this crisis is Klebsiella pneumoniae, a microorganism capable of causing severe infections while evading both antibiotics and the human immune system.

If the FDA ceases to be a predictable source of regulatory guidance, then China will gain a significant advantage in the race for biopharmaceutical supremacy.